Day 1—depart from Athens, Greece

Day 2—Mykonos, Greece

Day 3—lecture day at sea

Day 4—Corfu, Greece

Day 5—Drubovnik, Croatia

Day 6—Zadar, Croatia

Day 7—Split, Croatia

Day 8—debark ship in Venice, Italy

Dr. William Benefield Jr., Pharm D., BCPP, FASCP

University of Texas at San Antonio and Austin

Dr. William Benefield graduated with honors from Auburn University with a BS in Pharmacy and received his Doctorate in Pharmacy degree from the University of Texas at Austin and the University of Texas Health Center at San Antonio. Dr. Benefield completed his residency in Psychiatric Pharmacy Practice at the University of Texas Health Science Center at San Antonio. He has been board certified in Psychiatric Pharmacy since 1997 and is a founding member of CPNP. He is currently a Clinical Assistant Professor of Psychiatry at the University of Texas. He has practiced in the areas of developmental disabilities, hospice and long term care for the past 27 years. He has authored and co-authored chapters in Pharmacotherapy, the Pharmacotherapy Case Book, and Applied Therapeutics. He has presented at the national meetings of the ACCP, ASCP, American Epilepsy Society, American Academy of Neurology, and NCDEU.

ANXIETY DISORDERS

ACPE# 0043-9999-23-032-L01-P

Objectives:

1.   Review the clinical presentation  of generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, and social phobia / social anxiety disorder.
2.   Identify the common comorbidities that may complicate recognition and management for each disorder.
3.  Discuss evidence-based approaches to manage the symptoms of each disorder.
4.  Strategize treatment via review of patient case studies————————————————————————————————————————————————————————————————
   

   ADVERSE EFFECTS OF ANTIPSYCHOTIC THERAPY: MONITORING & MANAGEMENT

   ACPE# 0043-9999-23-033-L01-P

   Objectives:

   1.  Analyze the relationship between receptor binding affinities and the adverse effect profiles of antipsychotics.

5. 2.  Define metabolic syndrome and the criteria required for diagnosis.
6. 3.  Explain the mechanism / pathophysiology behind antipsychotic-induced metabolic syndrome.
7.  4.  Identify which antipsychotics have a greater risk for metabolic syndrome.
8.  5.  List the most common drug-induced movement disorders associated with antipsychotic therapy and their treatment options.
9.  6.  Compare the advantages and disadvantages of antipsychotics based on their adverse effect profiles.
10.  7.  Select the most appropriate antipsychotic for a patient based on adverse effect potential and past medical history.